22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
03:01 , May 6, 2017 |  BioCentury  |  Product Development

Finding gems in India

For Agios Pharmaceuticals Inc. , the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
21:00 , Mar 30, 2017 |  BC Extra  |  Clinical News

Paper: Targeting VISTA may benefit prostate cancer patients

Researchers said targeting immune checkpoint V-region immunoglobulin-containing suppressor of T cell activation (VISTA) may be useful in treating prostate cancer, a disease that has thus far responded poorly to immune checkpoint therapies. A group including...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

Aurigene, Curis deal

The partners amended a 2015 deal granting Curis options to license exclusive, worldwide rights outside of India and Russia to small molecule cancer compounds. Curis subsequently exercised its options to license two preclinical small molecule...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

CA-170: Phase I started

Curis began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate once-daily oral CA-170 in about 150 patients. Curis has exclusive, worldwide rights to the compound, except in India and Russia, from Aurigene (see...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Aurigene, Curis deal

Curis exercised its options to license two preclinical small molecule programs from Aurigene to treat cancer and cytokine-driven inflammatory and autoimmune diseases. The programs include CA-170 , an oral antagonist of PD-L1 and V-region immunoglobulin-containing...